<DOC>
	<DOCNO>NCT01593124</DOCNO>
	<brief_summary>This study investigate response vaginal cervical tissue exposure three vaginal product : hydroxyethyl cellulose ( HEC ) placebo , nonoxynol-9 ( N9 ) imiquimod ( IMQ ) cream .</brief_summary>
	<brief_title>Identification Novel Biomarkers Cervicovaginal Mucosal Inflammation</brief_title>
	<detailed_description>Each woman study evaluate 5 separate time : 1 . Baseline follicular phase menstrual cycle ; 2 . Baseline luteal phase menstrual cycle ; 3 . After 3 day ( 4 dose ) treatment HEC placebo ; 4 . After 3 day ( 4 dose ) treatment 4 % N-9 ; 5 . After 2 day ( 2 dose ) treatment IMQ . A subset 5 woman additional baseline visit follicular phase . The order N-9 IMQ treatment randomize . The study cross design . The per sequence treatment follow : Baseline follicular phase menstrual cycle , next baseline luteal phase menstrual cycle , next 3 day ( 4 dose ) treatment HEC placebo . At point study , half participant randomize N-9 treatment IMQ treatment . The remain half participant IMQ treatment N-9 treatment . All participant sample 5 timepoints describe .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<mesh_term>Nonoxynol</mesh_term>
	<criteria>1 . 21 45 year age , inclusive ; 2 . In good health , evidence history procedure screen enrollment visit without clinically significant systemic disease ; 3 . Not risk pregnancy , due surgical sterilization participant sexual partner , abstinence duration study , consistent condom use , nonhormonal IUD sex relationship . Note : If consistent condom user , must agree use condom without spermicide duration study . ; 4 . Have regular menstrual cycle ( every 2435 day ) past two cycle ; 5 . Willing able comply study procedures 1 . A clinically significant history abnormal pap smear ( write report ) evaluate treat , indicate , accord standard guideline ; 2 . It less 9 month since participant 's last depot medroxyprogesterone acetate ( DMPA ) injection 2 normal , spontaneous menses ( shorten 6 month participant least 2 normal spontaneous menses ) ; 3 . Use hormonal contraceptive method within past 3 month ( oral , transdermal , transvaginal , implant , intrauterine device ) without 2 subsequent , normal menses ; 4 . Surgery biopsy vulva , vagina , cervix ( include piercings ) within 30 day ; 5 . Pregnancy within past 3 month ; 6 . Currently breastfeed ; 7 . Current STI low genital tract infection ( include , limited HIV1 , HSV2 , Chlamydia trachomatis ( CT ) , Trichomonas vaginalis ( TV ) , Neisseria Protocol # D11119 Version 2.0 April 13 , 2012 10 gonorrhea ( NG ) , Hepatitis B , high risk HPV sub type Syphilis ) , yeast vaginitis bacterial vaginosis ( BV ) ; 8 . Current use chronic immunosuppressant ( example daily steroids daily nonsteroidal antiinflammatory drug [ NSAIDs ] ) ; 9 . Current presence vulvar , anal vaginal genital wart ; 10 . Current tobacco use amount ; 11 . Other condition , opinion investigator , would constitute contraindication participation study would compromise ability comply study protocol , major chronic illness include limited cancer , serious autoimmune disease , metabolic disorder major psychiatric disorder ( e.g. , schizophrenia ) ; 12 . Current participation drug device study , study ,</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Vaginal innate immune inflammatory response</keyword>
</DOC>